Full-Length IL-33 Promotes Inflammation but not Th2 Response In Vivo in an ST2-Independent Fashion

Expression of IL-33 is elevated in patients with pulmonary diseases, and full-length (not proteolytically processed) IL-33 is the predominant form in the lungs in health and disease. To determine whether activation of IL-33 is needed for functional effects, activities of full-length mouse and mature mouse (mm) forms of IL-33 were compared in vivo. Replication-deficient adenoviral constructs were used for gene delivery. Both isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mmIL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC. The different effects were not associated with differential release from IL-33–producing cells or by differences in subcellular distributions of IL-33 isoforms. Germline deficiency of the cell surface receptor chain ST2 abrogated the mmIL-33–induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mmIL-33 was not fully abrogated by the absence of ST2. The similar effects of IL-33 isoforms were associated with comparable regulation of gene expression, notably matrix metalloproteinases 3, 10, and 13. Thus, full-length IL-33 is functionally active in vivo in an ST2-independent fashion, and its effects are partially different from those of mature IL-33. The different effects of these isoforms, particularly the pro-Th2 effects of mature IL-33, are due to differential utilization of the IL-33R chain ST2, whereas their similar effects result from regulation of gene expression.

[1]  Xinchun Chen,et al.  IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cells , 2011, European journal of immunology.

[2]  M. Schmitz,et al.  The Dual Function Cytokine IL-33 Interacts with the Transcription Factor NF-κB To Dampen NF-κB–Stimulated Gene Transcription , 2011, The Journal of Immunology.

[3]  R. Le Goffic,et al.  Infection with influenza virus induces IL-33 in murine lungs. , 2011, American journal of respiratory cell and molecular biology.

[4]  M. Kawaguchi,et al.  Expression and Effects of IL-33 and ST2 in Allergic Bronchial Asthma: IL-33 Induces Eotaxin Production in Lung Fibroblasts , 2011, International Archives of Allergy and Immunology.

[5]  T. Mcclanahan,et al.  Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. , 2011, International immunology.

[6]  A. Keegan,et al.  Alternatively spliced variants of interleukin‐4 promote inflammation differentially , 2011, Journal of leukocyte biology.

[7]  A. Keegan,et al.  Splice isoforms of human interleukin‐4 are functionally active in mice in vivo , 2011, Immunology.

[8]  K. Yanaba,et al.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis , 2011, Clinical Rheumatology.

[9]  S. Kunkel,et al.  Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages , 2010, BMC Immunology.

[10]  Zhang Lianfeng,et al.  Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. , 2010, Immunology letters.

[11]  P. Paré,et al.  Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[12]  A. Abdollahi,et al.  Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis. , 2010, International journal of radiation oncology, biology, physics.

[13]  I. McInnes,et al.  Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.

[14]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[15]  W. Falk,et al.  Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. , 2010, Biochemical and biophysical research communications.

[16]  R. Flavell,et al.  Caspase-1, Caspase-8, and Calpain Are Dispensable for IL-33 Release by Macrophages1 , 2009, The Journal of Immunology.

[17]  I. McInnes,et al.  Role of interleukin 33 in human immunopathology , 2009, Annals of the rheumatic diseases.

[18]  Qutayba Hamid,et al.  Increased Expression of IL-33 in Severe Asthma: Evidence of Expression by Airway Smooth Muscle Cells1 , 2009, The Journal of Immunology.

[19]  M. Hayakawa,et al.  Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. , 2009, Biochemical and biophysical research communications.

[20]  Mingcai Li,et al.  Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. , 2009, Biochemical and biophysical research communications.

[21]  S. Cullen,et al.  Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. , 2009, Immunity.

[22]  J. Girard,et al.  The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 , 2009, Proceedings of the National Academy of Sciences.

[23]  C. Gabay,et al.  Interleukin-33 Is Biologically Active Independently of Caspase-1 Cleavage* , 2009, The Journal of Biological Chemistry.

[24]  L. Hummers,et al.  Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. , 2009, Arthritis and rheumatism.

[25]  A. Parker,et al.  Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. , 2008, Current opinion in molecular therapeutics.

[26]  Dirk E. Smith,et al.  IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. , 2008, International immunology.

[27]  C. Gabay,et al.  IL‐1, IL‐18, and IL‐33 families of cytokines , 2008, Immunological reviews.

[28]  F. Liew,et al.  IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice , 2008, Proceedings of the National Academy of Sciences.

[29]  J. Varani,et al.  Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. , 2007, Experimental and molecular pathology.

[30]  I. McInnes,et al.  IL‐33 is a chemoattractant for human Th2 cells , 2007, European journal of immunology.

[31]  N. Todd,et al.  Complex regulation of pulmonary inflammation and fibrosis by CCL18. , 2007, The American journal of pathology.

[32]  Delphine A. Lacorre,et al.  IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo , 2007, Proceedings of the National Academy of Sciences.

[33]  J. Papadimitriou,et al.  Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. , 2006, Arthritis and rheumatism.

[34]  I. Luzina,et al.  PKCα Mediates CCL18-Stimulated Collagen Production in Pulmonary Fibroblasts , 2006 .

[35]  J. Hasday,et al.  CCL18‐stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity , 2006, Journal of cellular physiology.

[36]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[37]  M. Hayakawa,et al.  T-helper type 2 cell-specific expression of the ST2 gene is regulated by transcription factor GATA-3. , 2005, Biochimica et biophysica acta.

[38]  S. Tominaga,et al.  The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. , 2003, Chest.

[39]  S. Tominaga,et al.  Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface , 2002, European journal of immunology.

[40]  F. Grosveld,et al.  Enforced Expression of GATA-3 in Transgenic Mice Inhibits Th1 Differentiation and Induces the Formation of a T1/ST2-Expressing Th2-Committed T Cell Compartment In Vivo1 , 2001, The Journal of Immunology.

[41]  S. Tominaga,et al.  Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. , 2001, American journal of respiratory and critical care medicine.

[42]  J. Gutiérrez-Ramos,et al.  Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology , 2001, The Journal of experimental medicine.

[43]  C. Meisel,et al.  Regulation and Function of T1/ST2 Expression on CD4+ T Cells: Induction of Type 2 Cytokine Production by T1/ST2 Cross-Linking1 , 2001, The Journal of Immunology.

[44]  D. J. Matthews,et al.  T1/St2-Deficient Mice Demonstrate the Importance of T1/St2 in Developing Primary T Helper Cell Type 2 Responses , 2000, The Journal of experimental medicine.

[45]  C. Meisel,et al.  Crucial Role of the Interleukin 1 Receptor Family Member T1/St2 in T Helper Cell Type 2–Mediated Lung Mucosal Immune Responses , 1999, The Journal of experimental medicine.

[46]  Andreas Radbruch,et al.  T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Roussel,et al.  Cloning and expression of murine interleukin-1 receptor antagonist in macrophages stimulated by colony-stimulating factor 1. , 1991, Blood.

[48]  Sherr,et al.  Cloning and Expression of Murine Interleukin-1 Receptor Antagonist in Macrophages Stimulated by Colony-Stimulating Factor , 2003 .

[49]  S. Weiss,et al.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury. , 2001, American Journal of Respiratory Cell and Molecular Biology.